QED Pharmaceutical Services picks SAS® Clinical Data Integration to help clients implement CDISC standards
QED levels the playing field for small drug developers seeking partnerships with large pharmaceutical companies
46th DIA Annual Meeting, WASHINGTON, D.C. (Jun. 14, 2010) – QED Pharmaceutical Services has licensed SAS® Clinical Data Integration to enable its drug development clients to more easily form partnerships with key biopharmaceutical companies. The win at QED, a global contract research organization (CRO) with offices in India and the United States, continues the strong market momentum for SAS Clinical Data Integration. SAS, the leader in business analytics software and services, offers a comprehensive portfolio of life sciences software solutions for pharmaceutical, biotechnology and medical device companies.
“The availability of SAS Clinical Data Integration has made it possible for QED to efficiently implement complex data standards such as the CDISC standards,” said Dr. Ramana Kuchibhatla, QED founder. “This allows us to help our clients - predominantly small and sometimes virtual biopharmaceutical companies - achieve important milestones despite their size. Compliance with the latest CDISC standards makes growing drug developers like our clients very attractive partners to large pharma companies that are looking to in-license successful drug development programs. The overall value created by SAS Clinical Data Integration to both QED as a service company and our clients by making them attractive partners and ensuring regulatory compliance is tremendous.”
QED also has uses other SAS products including SAS® Enterprise Business Intelligence. With the continuous knowledge base created by these systems, QED can offer cost-effective services for its clients. “It’s as if we have designed an efficient mechanical engine, and now, with little modification for each clinical trial, we can crank out CDISC-compliant data and get our clients’ datasets output in regulatory submission-ready formats,” said Kuchibhatla.
Why is SAS® Clinical Data Integration critical?
SAS Clinical Data Integration provides the foundation organizations need to deliver safety, efficacy and strategic, cross-study analyses. The solution brings repeatability and automation to the industry need to transform, manage and verify the creation of data standards, such as those from CDISC. SAS Clinical Data Integration facilitates operational data management efficiencies that speed delivery of business insight from clinical information. Using SAS, companies are delivering cleaner, more standard data for analysis and submission. In order to provide rapid access to clinical data to accelerate analysis and decision making in clinical research, SAS Clinical Data Integration will provide interoperability with Medidata Rave® using CDISC operational data model (ODM) standards.
Other SAS® for Life Sciences customers include Alcon, AstraZeneca, Eli Lilly and Company, McKesson and Monsanto. SAS will demonstrate its life sciences products in Booth #1601 during the 46th DIA Annual Meeting in Washington, D.C., June 13 to 16, 2010.
About QED Pharmaceutical Services
QED Pharmaceutical Services is a leading global Contract Research Organization (CRO) with offices in Hyderabad, India, and Research Triangle Park, North Carolina. QED specializes in conducting Phase I through Phase IV clinical trials and other clinical and regulatory research services that cater to biotechnology and pharmaceutical product development. QED was established in 2007 by Dr. Ramana Kuchibhatla. For more information about QED, visit http://www.qedpharma.com/
SAS is the leader in business analytics software and services, and the largest independent vendor in the business intelligence market. Through innovative solutions delivered within an integrated framework, SAS helps customers at more than 45,000 sites improve performance and deliver value by making better decisions faster. Since 1976 SAS has been giving customers around the world
The Power to Know®